The research

Ovarian cancer: a new blood test for early diagnosis

A molecular ‘marker’ capable of detecting precancerous lesions that escape detection by traditional tests has been identified. The findings, published in *Nature Medicine*, open up new prospects for early diagnosis. However, the test has yet to be validated.

Doctor consulting patient hands closeup. Patient sitting at doctor office. Diagnostic, prevention of women diseases, healthcare, medical service, consultation or education, healthy lifestyle concept Liudmila Dutko - stock.adobe.com

3' min read

Translated by AI
Versione italiana

3' min read

Translated by AI
Versione italiana

Detecting an ovarian tumour whilst it is still at an early stage, before it has become invasive, is one of the major challenges in oncology. Ovarian tumours, for example, develop without causing any recognisable symptoms and are therefore often diagnosed when the disease is already at an advanced stage, as there are no screening tests available. However, new research published in Nature Medicine suggests that one of the most aggressive forms of ovarian cancer may release valuable clues into the bloodstream, long before it can be detected using currently available imaging techniques and tumour markers.

The ‘message in a bottle’ from a tumour in the blood, even at an early stage

The potential breakthrough comes from a molecule called Tu-stroma, a sort of ‘message in a bottle’ that circulates in the blood within tiny vesicles released by cells. Researchers have discovered that this signal may already be present in precancerous lesions of the fallopian tubes, from which high-grade serous carcinoma – one of the most aggressive forms of ovarian cancer – can develop. The study analysed blood samples from 506 women; of these, 43 had precancerous lesions, 232 had high-grade serous carcinoma, 88 had benign adnexal masses and 143 were tumour-free controls. The samples were divided into a group used to develop the test and another, independent group to assess its performance (validation group).

Loading...

The results of this study are very interesting. In the validation group, the new marker identified around 95 per cent of precancerous lesions and tumours diagnosed at an early stage. Even more interesting is the comparison with CA 125, the tumour marker routinely used in the clinical assessment of ovarian cancer, which, however, proves to be unreliable in the earliest stages.

Tu-stroma outperforms traditional tumour markers in terms of accuracy

When the researchers compared the ability of the two tests to distinguish precancerous lesions from women without cancer, Tu-stroma achieved a high diagnostic accuracy rate, significantly higher than that of CA 125, confirming that the new test has a markedly superior ability to distinguish between the two.

This difference is particularly significant because some precancerous lesions and early-stage tumours still had CA125 levels within the normal range, whilst the new marker was already elevated. Conversely, in several women with benign conditions that can cause an increase in CA125, Tu-stroma levels remained low.

The test has also shown promise in pre-menopausal women, in whom the interpretation of CA125 levels can be complicated by the presence of benign gynaecological conditions. Furthermore, in the groups examined, Tu-stroma was not consistently elevated in the presence of endometriosis, inflammatory diseases or eleven other types of cancer.

Can this new blood test already be used as a screening test?

The Tu-stroma test shows great promise but is not yet ready for use in clinical practice. The study published in *Nature Medicine* is retrospective in nature and compared samples from women with already established diagnoses. This type of research can yield very promising results, but it does not prove that the test would work just as well if offered to apparently healthy women, specifically as a screening test. And when a disease is relatively rare, as is the case with ovarian cancer, even a highly accurate test can generate many false alarms.

For this reason, the study’s authors suggest that a possible initial area of application in clinical practice could be the monitoring of women at high hereditary risk (carriers of pathogenic variants of the BRCA genes, the so-called ‘Angelina Jolie gene’) or the assessment of ovarian masses of uncertain nature, rather than as a universal screening test for all women. Prospective studies will, however, be needed to establish whether the new marker can genuinely bring forward diagnosis, guide clinical decisions and, above all, help reduce mortality in a general population setting, i.e. through universal screening.

The most interesting finding of this study is the prospect of detecting the biological signs of a tumour whilst it is still at a precancerous stage – that is, before the disease manifests itself in an invasive form. As we have seen, this is a possibility that still needs to be verified, but one that could pave the way for the early diagnosis of one of the most difficult female cancers to detect.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti